VPIM
ALLO icon

Vanguard Personalized Indexing Management’s Allogene Therapeutics ALLO Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$216K Buy
88,523
+20,735
+31% +$41.6K ﹤0.01% 1779
2025
Q4 		$92.9K Sell
67,788
-17,932
-21% -$23.7K ﹤0.01% 1814
2025
Q3 		$106K Buy
85,720
+14,032
+20% +$16.7K ﹤0.01% 1810
2025
Q2 		$81K Buy
71,688
+46,398
+183% +$61.7K ﹤0.01% 1765
2025
Q1 		$36.9K Buy
25,290
+4,777
+23% +$9.01K ﹤0.01% 1703
2024
Q4 		$43.7K Buy
20,513
+4,716
+30% +$11.6K ﹤0.01% 1708
2024
Q3 		$44.2K Buy
15,797
+5,398
+52% +$14.4K ﹤0.01% 1687
2024
Q2 		$24.2K Buy
+10,399
New +$30.7K ﹤0.01% 1635

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return